United Therapeutics
- Market cap
- 23.38B
- P/E (TTM)i
- 19.53
- P/Bi
- 3.65
- EPSi
- 27.86
- Div yieldi
- 0.00%
- 52W posi
- 68%
Anonymous reader poll. Unscientific, not investment advice.
United Therapeutics last traded at 545.00, up 0.62% on the session. The company carries a market value of roughly 23.38B, the #836 most valuable US-listed company we track. The trailing P/E of 19.42 is 22% above its five-year average of 15.97. The 8 analysts covering the stock are, on balance, at Buy, targeting an average of 629.63 (+16%). Over the past year the stock has ranged from 409.07 to 609.35; it now sits 68% up that band.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 days.
- Recent price momentum is +8.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 6.5% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 19.2x | Better than 50% |
| Forward P/E | 19.2x | Better than 45% |
| Price / Sales | 7.4x | Better than 16% |
| P/E vs own 5-yr range | 88th pctl | Better than 18% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 18.0% | Better than 81% |
| Net income CAGR (3Y) | 22.4% | Better than 76% |
| Free cash flow CAGR (3Y) | 16.0% | Better than 60% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 87.9% | Better than 97% |
| Operating margin | 47.7% | Better than 97% |
| Net margin | 41.9% | Better than 96% |
| Return on equity | 19.7% | Better than 66% |
| Return on invested capital | 17.7% | Better than 80% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -4.8% | Better than 42% |
| 6-month return | -5.2% | Better than 30% |
| 12-month return (ex latest month) | 7.6% | Better than 41% |
| Distance below 52-week high | 12.0% | Better than 70% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.6x | Better than 95% |
| Debt to assets | 4.1% | Better than 88% |
| Interest coverage | 88.9x | Better than 92% |
| Free cash flow / net income | 77.6% | Better than 24% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 75.0% | Better than 51% |
| Upside to average target | 17.4% | Better than 33% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 541.62
- Open
- 542.41
- Day range
- 541.90 - 558.30
- Avg price
- 547.75
- Volume
- 1.01M
- Turnover
- 550.65M
- Turnover ratei
- 2.56%
- Volume ratioi
- 0.60
- Amplitudei
- 3.03%
- 52-week rangei
- 409.07 - 609.35
Valuation
- P/Ei
- 19.56
- P/E (TTM)i
- 19.53
- P/Bi
- 3.65
- EPSi
- 27.86
- Book value / shi
- 149.22
- Net profit
- 1.19B
- Net assets
- 6.40B
Share structure
- Market cap
- 23.38B
- Float capi
- 21.37B
- Shares out
- 42.89M
- Float sharesi
- 39.21M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
10.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+24.05M net over the window
Short interest
- Shares short
- 2.80M
- % of floati
- 6.53%
- Days to coveri
- 3.90
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of United Therapeutics (UTHR)?
United Therapeutics last traded at 545.00. The quote on this page refreshes every few seconds while US markets are open.
What is United Therapeutics's market cap?
About 23.38B.
What is the P/E ratio of United Therapeutics?
The trailing twelve-month P/E is 19.53, above its own 5-year average of 15.97 — toward the top of its historical range (87.55% percentile). See the Valuation tab for the full history.
Does United Therapeutics pay a dividend?
United Therapeutics does not currently pay a regular dividend.
Is United Therapeutics a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 629.63, which implies 15.5% upside from the current price. This is not investment advice.
What is United Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates United Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 06:19:20 · For reference only, not investment advice and not tailored to your situation.